Skip to main content
. 2021 Jun 15;9(8):4076–4084. doi: 10.1002/fsn3.2339

TABLE 4.

Subgroup analysis in subject with large VFA

Sudachi Placebo
Baseline 12 weeks p Wilcoxon Baseline 12 weeks p Wilcoxon
Markers on glycemic control
HbA1c (%) 5.86 ± 0.70 5.84 ± 0.62 .699 5.70 ± 0.36 5.67 ± 0.37 .187
Fasting glucose (mg/dl) 90.9 ± 11.5 94.1 ± 8.4 .384 97.5 ± 13.1 97.5 ± 10.9 .709
Fasting insulin (uU/ml) 6.61 ± 1.9 7.08 ± 2.0 .265 6.21 ± 3.1 7.85 ± 4.3 .324
HOMA IR 1.48 ± 0.44 1.67 ± 0.51 .438 1.54 ± 0.86 1.87 ± 0.97 .349
HOMA β 101.5 ± 54.4 84.9 ± 27.6 .453 66.3 ± 34.1 88.6 ± 56.8 .785
Lipid profile
Triglyceride (mg/dl) 118.0 ± 34.1 133.4 ± 56.7 .185 126.5 ± 39.4 134.7 ± 72.4 .181
Total cholesterol (mg/dl) 214.3 ± 35.9 210.3 ± 36.0 <−0.05 242.5 ± 20.5 237.04 ± 18.1 .079
HDL cholesterol (mg/dl) 52.9 ± 14.5 52.1 ± 15.8 .923 55.3 ± 10.5 54.8 ± 7.0 .925
LDL cholesterol (mg/dl) 132.8 ± 31.0 120.9 ± 30.3 <.001 171.0 ± 8.3 166.3 ± 21.5 .282
LDL‐C/HDL‐C 2.67 ± 0.86 2.45 ± 0.75 <.001 3.17 ± 0.51 3.10 ± 0.73 .096
Body fat analysis
Body fat (%) 30.6 ± 6.2 29.6 ± 6.4 .089 28.9 ± 4.6 28.6 ± 4.6 .903
TFA (cm2) 318.8 ± 60.3 309.8 ± 63.1 <.001 313.4 ± 41.3 316.3 ± 41.5 .908
SFA (cm2) 194.7 ± 60.0 188.9 ± 57.8 <.001 179.3 ± 41.0 182.6 ± 36.6 .964
VFA (cm2) 124.1 ± 14.5 121.0 ± 23.6 <.001 134.1 ± 11.7 133.7 ± 24.1 .884
VFA/SFA 0.68 ± 0.20 0.58 ± 0.21 <.001 0.79 ± 0.27 0.76 ± 0.26 .853
Waist circumference (cm) 95.3 ± 4.7 94.5 ± 4.8 .058 98.9 ± 7.1 98.1 ± 5.4 .855
Blood pressures (BP, mm Hg)
Systolic BP 135.1 ± 15.2 140.8 ± 8.3 .373 145.8 ± 25.8 142.7 ± 19.9 .817
Diastolic BP 82.8 ± 10.8 85.8 ± 10.7 .583 91.0 ± 13.9 88.0 ± 10.1 .678
Hypertension (>140/90 mm Hg) 2 2 3 3
Heart rate (bpm) 71.4 ± 8.7 70.9 ± 8.9 .913 70.8 ± 11.2 69.8 ± 11.5 .918